ArticleClinical and vaccine immunology : CVI2013
Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early lyme disease.
Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Multiplexed single-tier immunoassay for improved Lyme disease diagnosis across all disease stages.Research square · 2026Article
- Atypical multidrug-resistant serotype 1Frontiers in veterinary science · 2026Article
- Genomic characterization of clinical Borrelia burgdorferi sensu lato isolates in the Netherlands over a thirty-year period.BMC genomics · 2025Article
- New Epitopes for the Serodiagnosis of Human Borreliosis.Microorganisms · 2024Article
- Rapid single-tier serodiagnosis of Lyme disease.Nature communications · 2024Article
- A Refined Human Linear B Cell Epitope Map of Outer Surface Protein C (OspC) From the Lyme Disease Spirochete,Pathogens & immunity · 2024Article
- Tick-Borne Co-Infections: Challenges in Molecular and Serologic Diagnoses.Pathogens (Basel, Switzerland) · 2023Review
- Epitope Mapping of BmpA and BBK32ACS infectious diseases · 2023Article
- Immunoblot Criteria for Diagnosis of Lyme Disease: A Comparison of CDC Criteria to Alternative Interpretive Approaches.Pathogens (Basel, Switzerland) · 2023Article
- Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease.Antibodies (Basel, Switzerland) · 2023Review
- A portable immunosensor provides sensitive and rapid detection of Borrelia burgdorferi antigen in spiked blood.Scientific reports · 2023Article
- Article
- Linear Peptide Epitopes Derived from ErpP, p35, and FlaB in the Serodiagnosis of Lyme Disease.Pathogens (Basel, Switzerland) · 2022Article
- Immunoreactivity of Polish Lyme Disease Patient Sera to SpecificDiagnostics (Basel, Switzerland) · 2021Article
- Article
- Laboratory Diagnosis of Lyme Borreliosis.Clinical microbiology reviews · 2021Review
- A Fully Automated Multiplex Assay for Diagnosis of Lyme Disease with High Specificity and Improved Early Sensitivity.Journal of clinical microbiology · 2020Article
- Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors.PloS one · 2020Article
- Article
- A multiplex serologic platform for diagnosis of tick-borne diseases.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Current serodiagnostic assays for Lyme disease are inadequate at detecting early infection due to poor sensitivity and nonspecificity that arise from the use of whole bacteria or bacterial proteins as assay targets; both targets contain epitopes that are cross-reactive with epitopes found in antigens of other bacterial species. Tests utilizing peptides that contain individual epitopes highly specific for Borrelia burgdorferi as diagnostic targets are an attractive alternative to current assays. Using an overlapping peptide library, we mapped linear epitopes in OspC, a critical virulence factor of B. burgdorferi required for mammalian infection, and confirmed the results by enzyme-linked immunosorbent assay (ELISA). We identified a highly conserved 20-amino-acid peptide epitope, OspC1. Via ELISA, OspC1 detected specific IgM and/or IgG in 60 of 98 serum samples (62.1%) obtained from patients with erythema migrans (early Lyme disease) at the time of their initial presentation. By comparison, the commercially available OspC peptide PepC10 detected antibody in only 48 of 98 serum samples (49.0%). In addition, OspC1 generated fewer false-positive results among negative healthy and diseased (rheumatoid arthritis and positive Rapid Plasma Reagin [RPR+] test result) control populations than did PepC10. Both highly specific and more sensitive than currently available OspC peptides, OspC1 could have value as a component of a multipeptide Lyme disease serological assay with significantly improved capabilities for the diagnosis of early infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.